RxDoctor Payments Data

Rafael Rivera Colon, MD

General Practice · Caguas, PRNPI 1134116668

Payments from drug & device makers

$1,005in general payments, 2019–2025

Across 18 payments — averaging $55.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$199
  • Merck$198
  • AstraZeneca$191
  • E.r. Squibb & Sons, L.L.C.$122
  • Boehringer Ingelheim$105
  • Genentech USA, Inc.$81
  • plus $109 from 3 others

What the payments were for

  • Food & beverage$99099%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,005 in reported general payments places this provider in the 85th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$3,076
Medicare patients
15
Services billed
38

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban123$95,965
JardianceEmpagliflozin83$64,420
SynthroidLevothyroxine Sodium604$54,075
FarxigaDapagliflozin Propanediol65$51,905
XareltoRivaroxaban40$41,344
JanuviaSitagliptin Phosphate18$25,069
JanumetSitagliptin Phos/Metformin Hcl39$24,465
Synjardy XrEmpagliflozin/Metformin Hcl14$18,641
Xigduo XrDapaglifloz Propaned/Metformin19$15,657
Diclofenac Potassium156$14,662
TradjentaLinagliptin18$13,570
Rivastigmine65$9,634
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate33$9,148
SymbicortBudesonide/Formoterol Fumarate37$8,671
Sucralfate75$8,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Jentadueto Xr, Spiriva Respimat$105$109,920140 claims
PfizerEliquis$15$95,965123 claims
AstraZenecaFarxiga, Symbicort$191$60,576102 claims
MerckJanuvia, Janumet$198$49,53557 claims
Johnson & JohnsonXarelto$199$41,34440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →